MX356789B - Composición de difenidol de liberación prolongada. - Google Patents

Composición de difenidol de liberación prolongada.

Info

Publication number
MX356789B
MX356789B MX2013000662A MX2013000662A MX356789B MX 356789 B MX356789 B MX 356789B MX 2013000662 A MX2013000662 A MX 2013000662A MX 2013000662 A MX2013000662 A MX 2013000662A MX 356789 B MX356789 B MX 356789B
Authority
MX
Mexico
Prior art keywords
prolonged
composition
release
diphenidol
release diphenidol
Prior art date
Application number
MX2013000662A
Other languages
English (en)
Other versions
MX2013000662A (es
Inventor
Resendiz Hernández Guadalupe
Original Assignee
Invekra S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invekra S A P I De C V filed Critical Invekra S A P I De C V
Priority to MX2013000662A priority Critical patent/MX356789B/es
Priority to CA2889283A priority patent/CA2889283C/en
Priority to US14/759,683 priority patent/US10188610B2/en
Priority to BR112015011351-6A priority patent/BR112015011351B1/pt
Priority to PCT/IB2014/000044 priority patent/WO2014111799A1/es
Priority to PE2015000603A priority patent/PE20150888A1/es
Publication of MX2013000662A publication Critical patent/MX2013000662A/es
Priority to GT201500038A priority patent/GT201500038A/es
Priority to DO2015000089A priority patent/DOP2015000089A/es
Priority to CL2015001128A priority patent/CL2015001128A1/es
Priority to CR20150275A priority patent/CR20150275A/es
Priority to ECIEPI201530460A priority patent/ECSP15030460A/es
Publication of MX356789B publication Critical patent/MX356789B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica de difenidol de liberación prolongada que comprende: a) de 15 a 50% de clorhidrato de difenidol; b) de 0.1 a 20% de uno o más agentes aglutinantes; c) de 5 a 90% de uno o más agentes diluentes; d) de 5 a 50% de uno o más agentes modificadores de la liberación; e) de 0.25 a 10% de uno o más agentes lubricantes; y f) 0.1 a 10% de agentes deslizantes. De manera preferida, esta composición farmacéutica se administra por vía oral y se encuentra en forma de tableta.
MX2013000662A 2013-01-16 2013-01-16 Composición de difenidol de liberación prolongada. MX356789B (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2013000662A MX356789B (es) 2013-01-16 2013-01-16 Composición de difenidol de liberación prolongada.
PE2015000603A PE20150888A1 (es) 2013-01-16 2014-01-15 Composicion de difenidol de liberacion prolongada
US14/759,683 US10188610B2 (en) 2013-01-16 2014-01-15 Prolonged-release diphenidol composition
BR112015011351-6A BR112015011351B1 (pt) 2013-01-16 2014-01-15 Composição farmacêutica na forma de tablete em camada única de difenidol de liberação sustentada
PCT/IB2014/000044 WO2014111799A1 (es) 2013-01-16 2014-01-15 Composición de difenidol de liberación prolongada
CA2889283A CA2889283C (en) 2013-01-16 2014-01-15 Prolonged-release diphenidol composition
GT201500038A GT201500038A (es) 2013-01-16 2015-02-19 Composicion de difenidol de liberacion prolongada.
DO2015000089A DOP2015000089A (es) 2013-01-16 2015-04-17 Composición de difenidol de liberación prolongada
CL2015001128A CL2015001128A1 (es) 2013-01-16 2015-04-29 Composicion farmaceutica de difenidol de liberación prolongada; util como agente antiemetico y antivertigo.
CR20150275A CR20150275A (es) 2013-01-16 2015-05-25 Composición de difenidol de liberación prolongada
ECIEPI201530460A ECSP15030460A (es) 2013-01-16 2015-07-15 Composición de difenidol de liberación prolongada

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013000662A MX356789B (es) 2013-01-16 2013-01-16 Composición de difenidol de liberación prolongada.

Publications (2)

Publication Number Publication Date
MX2013000662A MX2013000662A (es) 2014-07-16
MX356789B true MX356789B (es) 2018-06-12

Family

ID=51209070

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000662A MX356789B (es) 2013-01-16 2013-01-16 Composición de difenidol de liberación prolongada.

Country Status (11)

Country Link
US (1) US10188610B2 (es)
BR (1) BR112015011351B1 (es)
CA (1) CA2889283C (es)
CL (1) CL2015001128A1 (es)
CR (1) CR20150275A (es)
DO (1) DOP2015000089A (es)
EC (1) ECSP15030460A (es)
GT (1) GT201500038A (es)
MX (1) MX356789B (es)
PE (1) PE20150888A1 (es)
WO (1) WO2014111799A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108283625A (zh) * 2018-04-26 2018-07-17 江苏四环生物制药有限公司 一种盐酸地芬尼多片的制备方法
CN110638776A (zh) * 2019-10-25 2020-01-03 仁和堂药业有限公司 盐酸地芬尼多片的制备工艺
CN110638775A (zh) * 2019-10-25 2020-01-03 仁和堂药业有限公司 一种盐酸地芬尼多片剂及其应用
CN110934842A (zh) * 2019-11-26 2020-03-31 卓和药业集团有限公司 盐酸地芬尼多片的制备方法
CN112315925A (zh) * 2020-11-16 2021-02-05 仁和堂药业有限公司 盐酸米安色林片及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
WO1991006281A1 (fr) * 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Preparation gastrique
CN1935140A (zh) 2005-09-19 2007-03-28 长沙佰川医药科技开发有限责任公司 复方盐酸地芬尼多分散片剂及其制备方法
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2008146178A2 (en) * 2007-05-30 2008-12-04 Wockhardt Research Centre A novel tablet dosage form
KR101051630B1 (ko) * 2008-10-02 2011-07-26 한국유나이티드제약 주식회사 용출률과 복용편의성이 향상된 트리메부틴 서방정
CA2753057C (en) * 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug

Also Published As

Publication number Publication date
MX2013000662A (es) 2014-07-16
US10188610B2 (en) 2019-01-29
BR112015011351B1 (pt) 2021-11-23
CR20150275A (es) 2015-07-08
ECSP15030460A (es) 2017-08-31
BR112015011351A2 (pt) 2017-07-11
DOP2015000089A (es) 2015-05-15
WO2014111799A1 (es) 2014-07-24
US20150352051A1 (en) 2015-12-10
CA2889283C (en) 2020-12-29
GT201500038A (es) 2019-08-02
CL2015001128A1 (es) 2015-10-09
CA2889283A1 (en) 2014-07-24
PE20150888A1 (es) 2015-06-08

Similar Documents

Publication Publication Date Title
MX387322B (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
JOP20200122A1 (ar) مركبات مفيدة لتثبيط cdk7
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
SG11201811697SA (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
WO2016060996A3 (en) Interleukin-15 compositions and uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
HRP20210529T1 (hr) Inhibitori za mk2 i njihove uporabe
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MY191219A (en) Therapeutic agent for fibrosis
MX356789B (es) Composición de difenidol de liberación prolongada.
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2017012022A (es) Compuestos organicos.
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ICONKRETE 2012, S.L.

FG Grant or registration